Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models

This study finds BGB-A445, a non-ligand-competitive anti-OX40 antibody under clinical investigation, induces T cell activation, depletes regulatory T cells, shows robust antitumor efficacy in a mouse model, synergizes with anti-PD-1, and is superior to ligand-competitive ones, warranting further clinical study.

September 24, 2025


September 25 2025

September 24 2025

September 23 2025

September 22 2025

September 21 2025

September 20 2025

September 19 2025

September 18 2025

September 17 2025

September 16 2025

September 15 2025

September 14 2025

September 13 2025

September 12 2025

September 11 2025